Showing 1041-1050 of 9103 results for "".
Scientifically Speaking: Correcting and Avoiding Complications in Dark Skin Tones, Part 2 of 2
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-correcting-and-avoiding-complications-in-dark-skin-tones-part-2-of-2/19898/Advancements in energy-based devices mean that these tools can be used across a range of skin tones. But complications can and do still occur. In part two of a discussion on EBDs used in darker skin types, host Joel L. Cohen, MD reviews cases with Michelle Henry, MD, Omar Ibrahimi, MD, PhD, and JennWhat is the best thing you've done to improve your practice in the last year?
https://practicaldermatology.com/topics/practice-management/what-is-the-best-thing-you-ve-done-to-improve-your-practice-in-the-last-year/20279/The best thing I did to improve my practice was... PD Asks Ava Shamban, MD how she's improved her practice in the last year. Dr. Shamban says the best thing she did was to develop incentive and goals for her staff. Watch other responses to this question: Joel Gelfand, MDLex Icon: Lexington's Randy Waldman Speaks the Language of Successful Site Planning with Joel L. Cohen
https://practicaldermatology.com/topics/practice-management/lex-icon-lexington-s-randy-waldman-speaks-the-language-of-successful-site-planning-with-joel-l-cohen--ovevisoh/18901/How do you plan a brand new, state-of-the art surgical and clinical space that's accessible yet feels exclusive? Should you rent or buy? How do you balance your time? S. Randolph Waldman, MD answers these questions and more from series host Joel L. Cohen, MD in this edition of Best Practices.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.FDA Approves Axillary Hyperhidrosis Treatment; Study Examines Biologic Outcomes in Psoriasis
https://practicaldermatology.com/series/dermwire-tv/fda-approves-axillary-hyperhidrosis-treatment-study-examines-biologic-outcomes-psoriasis/26562/In this week's DermwireTV, the FDA approves a first-of-its-kind gel for axillary hyperhidrosis; a new analysis examines how smoking, BMI, and age affect biologic outcomes in psoriasis; and the CEO of Aerolase joins us to discuss the latest trends in the aesthetic laser market.The Use of Lasers and Energy-Based Devices in Patients with Richly Pigmented Skin
https://practicaldermatology.com/programs/practical-dermatology/the-use-of-lasers-and-energy-based-devices-in-patients-with-richly-pigmented-skin/18199/In the last of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Andrew Alexis, MD, a dermatologist from New York City and the President of the Skin of Color Society, Corey Hartman, MD, a dermatologist in Birmingham, Alabama, and Janiene Luke, MD, a dermatoloHow does chronic AD histopathology evolve from spongiosis-dominant lesions to lichenified, fibrotic plaques?
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/how-does-chronic-ad-histopathology-evolve-from-spongiosis-dominant-lesions-to-lichenified-fibrotic-plaques/48772/Christopher Bunick, MD, FAAD, discusses the roles of the six major cytokines that drive atopic dermatitis pathophysiology: IL-4, IL-13, IL-31, TSLP, IL-22, and IFN-γ.Time Is Hair: An Update on the Diagnosis and Treatment of Scarring Alopecias in Patients with Darker Skin Tones
https://practicaldermatology.com/programs/practical-dermatology/time-is-hair-an-update-on-the-diagnosis-and-treatment-of-scarring-alopecia-in-patients-with-darker-skin-tones/18198/In part two of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Dr. Andrew Alexis, a dermatologist from New York City and the President of the Skin of Color Society; Dr. Corey Hartman, a dermatologist in Birmingham, Alabama; and Dr. Janiene Luke, a dermatoloWeighing the Role of Network Meta-analysis for Choosing Biologic Therapies in Psoriatic Disease
https://practicaldermatology.com/programs/practical-dermatology/weighing-the-role-of-network-meta-analysis-for-choosing-biologic-therapies-in-psoriatic-disease/18189/There’s no paucity of studies for biologic therapies used to treat psoriatic disease, but the number of head-to-head trials comparing these agents is limited. Enter network meta-analysis, a statistical methodology that has emerged over the past few years to compare medication. Philip Mease, MD, a clCounseling Points for Patients Concerned About Long-term Immune Modulation
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37164/Practical Dermatology Editorial Board member Peter Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine, lists some of the most important counselling points for patients concerned about long-term immune modulation with newer sys